NEW YORK, NY / ACCESSWIRE / October 14, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on Pressure BioSciences, Inc. (OTCQB: PBIO).

The report is available here: PBIO October 2016 Update Note. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report will be available on all of these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

Highlights from the update note are as follows:

Robust growth in 2Q16 for PBIO

PBIO has reported growth for two consecutive quarters, with 2Q16 revenues coming in at $510,963, up 23.7% from the year ago period. For the first half of the year, revenues rose by 19.7% to reach $1,021,441. Importantly, the company has achieved this performance even as revenues from research grants have fallen. Indeed, revenue from Products & Services grew by 42% in 2Q16 with strong instrument sales and record sales of consumables. In our view, while grant revenues are valuable in that they provide high margin non-dilutive funding, the trend in products and services revenues are more illustrative of the company's underlying performance in the market. The strong results mark the second consecutive quarter that PBIO has generated revenues in excess of $500,000, and we were encouraged by management commentary that it expected both continued top line growth and well as a return of high margin grant revenues in the near future.

Successful launch of next gen Barocycler 2320EXTREME

We were pleased to see that PBIO completed the build and shipment of the first five Barocycler 2320EXTREME instrument systems. This upgrade had been in development for more than 1.5 years and represents a significant advancement of the Barocycler line at PBIO. We expect the company to move aggressively to commercialize the Barocycler 2320 EXTREME, both through its own sales and marketing efforts, as well as via its strategic co-marketing agreement with SCIEX, a global life sciences company and a leading provider of mass spectrometry instruments.

Maintain target of $1.75 for PBIO

2Q16 results came in largely with our expectations that PBIO would continue to grow in 2016. PBIO shares are up over 80% since we initiated coverage on the company, with the success coming largely from a management team that has followed through on its vision to create a new market for its PCT products and services. With PBIO's next generation product lines now on the market, the company is focused on sales and execution. Supported by its own sales efforts and a co-marketing agreement with mass spectrometry leader SCIEX, PBIO may be approaching a key inflection point for sales growth. Considering this, we are maintaining our price target of $1.75, which represents substantial upside from the recent price of $0.35.

Please review important disclosures on our website at www.seethruequity.com.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery, drug discovery & design, and forensics areas. Customers also use our products in other areas, such as bio-therapeutics characterization, soil & plant biology, vaccine development, and counter-bioterror applications.

About SeeThruEquity

Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion.

SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry's most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity